Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + bortezomib + temozolomide
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination therapy consisting of bevacizumab (a monoclonal antibody targeting VEGF), bortezomib (a proteasome inhibitor), and temozolomide (an alkylating agent). This regimen is primarily investigated for recurrent glioblastoma, where bortezomib may enhance temozolomide's effectiveness by depleting the MGMT enzyme and blocking autophagy, while bevacizumab inhibits angiogenesis.
- Other names
- temozolomide + bevacizumab + bortezomib
02
Targets
26S proteasomeDNAAGT (O6-methylguanine-DNA methyltransferase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + bortezomib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + bortezomib + temozolomide.